Dr. Sarah Sammons, MD
Claim this profileDuke University Medical Center
Area of expertise
Breast Cancer
Sarah Sammons, MD has run 9 trials for Breast Cancer. Some of their research focus areas include:
Breast Cancer
Sarah Sammons, MD has run 2 trials for Breast cancer. Some of their research focus areas include:
Affiliated Hospitals
Duke University Medical Center
Dana Farber Cancer Institute
Clinical Trials Sarah Sammons, MD is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting
2 awards
Phase 3
12 criteria
Datopotamab Deruxtecan
for Breast Cancer with Brain Metastases
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)
Recruiting
1 award
Phase 2
More about Sarah Sammons, MD
Clinical Trial Related
2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Sarah Sammons, MD has experience with
- Abemaciclib
- Fulvestrant
- Trastuzumab
- Pertuzumab
- Datopotamab Deruxtecan
- Aromatase Inhibitor (AI)
Breakdown of trials Sarah Sammons, MD has run
Breast Cancer
Breast cancer
Endometrial Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sarah Sammons, MD specialize in?
Sarah Sammons, MD focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 negative.
Is Sarah Sammons, MD currently recruiting for clinical trials?
Yes, Sarah Sammons, MD is currently recruiting for 2 clinical trials in Durham North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Sarah Sammons, MD has studied deeply?
Yes, Sarah Sammons, MD has studied treatments such as Abemaciclib, Fulvestrant, Trastuzumab.
What is the best way to schedule an appointment with Sarah Sammons, MD?
Apply for one of the trials that Sarah Sammons, MD is conducting.
What is the office address of Sarah Sammons, MD?
The office of Sarah Sammons, MD is located at: Duke University Medical Center, Durham, North Carolina 27710 United States. This is the address for their practice at the Duke University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.